Comparison of high- and low-dose 4-factor prothrombin complex concentrate for the emergent reversal of oral Factor Xa inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-021-02412-8
Abstract: Even though there are several reversal strategies available for oral Factor Xa inhibitor associated coagulopathies, 4-factor prothrombin complex concentrate (4F-PCC) is used commonly as the primary reversal agent at many institutions. A dose of 50… read more here.
Keywords: low dose; oral factor; high dose; dose group ... See more keywords
876: EVALUATION OF 4F-PCC IN THE MANAGEMENT OF MAJOR BLEEDING ASSOCIATED WITH ORAL FACTOR XA INHIBITORS
Sign Up to like & getrecommendations! Published in 2019 at "Critical Care Medicine"
DOI: 10.1097/01.ccm.0000551625.21969.85
Abstract: Learning Objectives: Bleeding caused by oral anticoagulants is a concerning drug safety problem. Given the sparse data available to support an optimal management strategy, this study aims to perform a comprehensive analysis of the safety… read more here.
Keywords: oral factor; pcc; bleeding associated; bleeding ... See more keywords
Oral factor Xa inhibitors and risk of subdural hematoma
Sign Up to like & getrecommendations! Published in 2020 at "Neurology"
DOI: 10.1212/wnl.0000000000009826
Abstract: Objective Subdural hematomas (SDHs) are an uncommon, but important, complication of anticoagulation therapy. We hypothesized that the risks of SDH would be similar during treatment with oral factor Xa inhibitors compared with aspirin. Methods We… read more here.
Keywords: factor inhibitors; oral factor; inhibitors risk; compared aspirin ... See more keywords